number of access : ?
number of downloads : ?
ID 114800
Author
Bando, Hiroshi Tokushima University|Japan low carbohydrate diet promotion association KAKEN Search Researchers
Keywords
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Canagliflozin Cardio-Vascular Assessment Study (CANVAS)
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)
Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study
Content Type
Journal Article
Description
Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.
Journal Title
Diabetes Research : Open Access
Publisher
Asploro
Volume
2
Issue
S1
Start Page
9
End Page
13
Published Date
2020-01-30
Rights
© 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences